Authors’ Reply to Whitlock: Perispinal Etanercept for Post-Stroke Neurological and Cognitive Dysfunction: Scientific Rationale and Current Evidence
KeywordsNeuropathic Pain Etanercept Escitalopram Certolizumab Pegol Neurological Improvement
The authors of this article have each been involved, over the course of more than a decade, in the basic science and/or clinical investigation of tumor necrosis factor (TNF) mechanisms involving the brain, i.e. in neuroinflammation research [1, 2, 3, 4, 5, 6, 7, 8, 9, 10, 11, 12, 13, 14, 15, 16]. One of the aims of our 2014 review was to bring together the increasing scientific evidence, from multiple fields of investigation and multiple academic centers that support a central role of neuroinflammation in the pathogenesis of post-stroke neurological dysfunction . In 2014, neuroinflammation has emerged as an area of increased international research interest, with intense interest in Europe and a new neurology journal devoted to this specific field [18, 19, 20].
Novel scientific discoveries, synthesized with previous scientific evidence, provide a framework for the scientific rationale underlying the rapid effects of perispinal etanercept on brain pathology [9, 13, 16, 21, 22, 23, 24, 25, 26, 27, 28]. This framework includes the discovery, in 2011, through the use of functional magnetic resonance imaging (fMRI), that within 24 h after neutralization of TNF by systemic intravenous administration of infliximab, nociceptive activity in the thalamus and somatosenoric cortex, as well as activation of the limbic system, was blocked . In 2013, a single systemic subcutaneous dose of another biologic TNF inhibitor, certolizumab pegol, was found to produce a rapid decrease in disease-related fMRI brain activity in rheumatoid arthritis patients, which preceded both clinical and structural responses to the drug . Just this week it was reported that a single dose of an antidepressant, the selective serotonin reuptake inhibitor escitalopram, dramatically alters functional connectivity throughout the whole brain in healthy subjects within 3 hours of the dose . The rapid and profound effect that antidepressant drugs have on the production of TNF in the brain was first demonstrated by Ignatowski and Spengler in 1994 . Antidepressant administration (desipramine) to rats prevented neuron-associated TNF production, as demonstrated by staining for TNF in the locus coeruleus and hippocampus . This was demonstrated to occur within 24 h after drug administration [29, 30]. These findings, along with the scientific evidence previously considered in our 2014 review, demonstrate that rapid effects of perispinal etanercept are entirely compatible with brain physiology as it is understood today [9, 13, 14, 16, 17, 21, 23, 25, 26, 27, 31, 32, 33, 34, 35, 36, 37].
The narrow definition of epidemiology is the study of the distribution of diseases in a population. The broader definition—an inductive science of biological inferences derived from observations—is more appropriate when relating EBM principals to clinical decision making … . The use of Bradford-Hill Criteria enhances evidence-based recommendations .
Explicit consideration of the Bradford Hill criteria may facilitate appreciation of the scientific rationale and evidence regarding pathophysiology underlying innovative therapeutic decision making [17, 40, 41, 43, 45].
Sometimes the effect of a medical intervention is so surprisingly strong, against the background knowledge of ‘usual prognosis’, that a case report or case series suffices to convince .
Case reports and case series have their own role in the progress of medical science. They permit discovery of new diseases and unexpected effects (adverse or beneficial) as well as the study of mechanisms, and they play an important role in medical education. Case reports and series have a high sensitivity for detecting novelty and therefore remain one of the cornerstones of medical progress; they provide many new ideas in medicine .
Given that randomized, controlled trials have not and often cannot be done for many clinical interventions, much of the clinical care provided in neurology (and all other specialties in medicine) would necessarily be considered unsubstantiated, if observational studies are discounted from consideration … the popular belief that randomized, controlled trials inherently produce gold standard results, and that all observational studies are inferior, does a disservice to patient care, clinical investigation, and education of health care professionals .
“Most health care decisions, especially by clinicians and patients, are based on incomplete evidence. This process could be improved with better access to transparent, credible, and concise yet complete summaries of the available evidence and its strength, whether or not it is conclusive and whether or not it includes RCTs” .
Authorities in the field of evidence-based medicine have specifically addressed the fact that some treatments have effects that are “… so dramatic that randomised trials are unnecessary” . Each of the authors has personally observed the unmistakable rapid neurological improvement produced by perispinal etanercept in patients with chronic, stable, baseline neurological dysfunction [8, 9, 10, 24, 26, 27, 32, 61]. The distinctive pattern of neurological improvement that often ensues following perispinal etanercept injection, documented in published digital video and written format, provides striking scientific evidence of a therapeutic effect [32, 62].1 These results are supported by a diverse variety of additional clinical and basic science studies that have specifically utilized etanercept as a therapeutic agent [8, 9, 10, 11, 12, 14, 17, 21, 24, 25, 26, 27, 32, 61, 63, 64, 65, 66, 67, 68, 69, 70, 71, 72, 73, 74, 75, 76, 77, 78]. Our recent review presents a detailed overview of the scientific evidence that supports the mechanistic reasoning utilized [17, 45, 48]. There are no gaps in the pathophysiological mechanisms discussed; the inferential chain is complete [17, 48]. The published, peer-reviewed perispinal etanercept scientific literature provides more than a decade of scientific support that includes detailed case studies documenting rapid and sustained neurological improvement in patients with neurological dysfunction that had long been unchanged prior to perispinal etanercept administration [8, 9, 10, 11, 12, 13, 14, 16, 24, 25, 26, 27, 32, 61, 74, 75, 76, 79, 80, 81, 82].
Antagonism of pro-inflammatory cytokines by specific antibodies represents a compelling therapeutic strategy to improve neurological outcome in patients after intracerebral hemorrhage .
With direct blood extravasation into brain, secondary inflammation is a substantial feature. Drugs which reduce neuroinflammation enhance functional recovery .
… the years-long interval between the stroke event and rapid clinical improvement described in these patients is consistent with experimental evidence that TNF generation persists in the CSF for very much longer (10 months plus) than in the serum (gone in 6 h)…. In this report each patient’s pre-treatment state provided an internal control. In practice, these individual pre-treatment comparisons are highly valid, since the likelihood of rapid spontaneous return of function is remote this long after the stroke event. Moreover, since no two stroke outcomes are the same, such internal controls allow precise before and after clinical comparison in a phenotypically heterogeneous condition .
There are now multiple, reported RCTs of etanercept for neurological indications that have shown etanercept to be superior to placebo [64, 65, 66, 69, 71]. The character, magnitude and reproducibility of patient recovery documented following perispinal etanercept for chronic post-stroke neurological dysfunction is unequivocal evidence of a therapeutic effect [8, 9, 12, 17, 24, 25, 26, 27, 32, 74].
Whitlock further errs in his analogy comparing the effects of opiates and etanercept for neuropathic pain . Exerting physiological effects that are distinct from those produced by opiates, TNF blockade using etanercept for treatment of neuropathic pain is a disease-modifying therapy that directly addresses a fundamental cause of the disorder, i.e. excess TNF [1, 63, 67, 68, 70, 72, 73, 77, 78, 84]. The authors each reported favorable effects of TNF blockade for the treatment of neuropathic pain, beginning more than a decade ago [1, 11, 12, 76]. To date, there are four favorable double-blind, randomized controlled trials of etanercept for sciatica and other forms of spinal neuropathic pain that have been completed [64, 65, 69, 71]. In addition, the basic science evidence supporting a therapeutic, disease-modifying effect of etanercept for the treatment of neuropathic pain continues to increase [1, 63, 67, 68, 70, 72, 73, 77, 78, 84]. It is of significant interest that recent evidence suggests that the early analgesic effects of biologic TNF inhibitors in patients with rheumatoid arthritis may be directly mediated, not peripherally but rather by rapid brain effects of the biologic TNF inhibitor .
There was no evidence that placebo interventions in general have clinically important effects .
Placebo effects do not produce the life-changing neurological improvements that have been documented and observed by each of the authors and others following perispinal etanercept injection [14, 25, 26, 32, 43]. In view of the distinctive character, quality and reproducibility of the clinical data, and the basic science evidence that supports the entire inferential chain, it would be a systematic error to deny the published, peer-reviewed evidence and characterize the reported clinical results of perispinal etanercept for post-stroke neurological dysfunction as anything less than a therapeutic breakthrough [8, 9, 10, 11, 12, 14, 17, 21, 24, 25, 26, 27, 32, 48, 61, 63, 64, 65, 66, 67, 68, 69, 70, 71, 72, 73, 74, 75, 76, 77, 78]. Those scientists who have recognized TNF antagonism for this indication as a “compelling therapeutic strategy” are exactly in line with the guidance to “translate best neuroscience, including animal and human studies, into poststroke recovery research and clinical care” that is the published consensus recommendation of world stroke leaders .
Etanercept is providing billions of dollars of yearly income to its manufacturers. These drug manufacturers are the only entities that possess the combination of regulatory expertise and financial capability necessary to achieve regulatory approval for these essential novel therapeutic indications. The strength of the emerging evidence argues for joint industry–government–academic cooperation to facilitate overcoming the substantial translational barriers that exist for such an innovative therapeutic approach.
Further digital video documentation at https://vimeo.com/user5534662/review/85796991/4385338257; https://vimeo.com/user5534662/review/85477199/2aa9b2c6f8 and http://www.vimeo.com/18550399.
Acknowledgments and Conflict Disclosure
Edward Tobinick has multiple issued and pending US and foreign patents, assigned to TACT IP, LLC, which claim methods of use of etanercept for the treatment of neurological disorders, including, but not limited to, US patents 6419944, 6537549, 6982089, 7214658, 7629311, 8119127, 8236306 and 8349323, all assigned to TACT IP, LLC; and Australian patent 758523. Dr. Tobinick is the founder of the Institute of Neurological Recovery (INR), a group of medical practices that utilize perispinal etanercept as a therapeutic modality, and also train physicians; he is also the CEO of TACT IP, LLC. Tracey Ignatowski and Robert Spengler have been expert witnesses for the INR. Tracey Ignatowski and Robert Spengler’s professional activities include their work as Co-Directors of Neuroscience at NanoAxis, LLC, a company formed to foster the commercial development of products and applications in the field of nanomedicine, which include novel methods of inhibiting TNF. This article represents the authors’ own work in which NanoAxis, LLC, was not involved. No funding was received for this letter.
- 5.Ignatowski TA, Spengler RN. Cytokines in synaptic function. In: Berczi I, Szentivanyi A, editors. Cytokines and the brain. NeuroImmune biology. Vol 6. Amsterdam: Elsevier; 2008. p. 111–43.Google Scholar
- 7.Ignatowski TA, Gerard BA, Bonoiu AC, Mahajan S, Knight PR, Davidson BA, et al., editors. Reduction of tumor necrosis factor (TNF) in the hippocampus alleviates neuropathic pain perception. Proceedings of the 4th International Congress on Neuropathic Pain; 2013. pp 29–35.Google Scholar
- 8.Tobinick E, Gross H, Weinberger A, Cohen H. TNF-alpha modulation for treatment of Alzheimer’s disease: a 6-month pilot study. Med Gen Med. 2006;8(2):25.Google Scholar
- 14.Griffin WS. Perispinal etanercept: potential as an Alzheimer therapeutic. J Neuroinflamm. 2008;5:3.Google Scholar
- 19.NEURON. Call for proposals for “European Research Projects on Neuroinflammation”, NEURON. 2014. http://www.neuron-eranet.eu/en/522.php. Accessed 9 Oct 2014.
- 20.Ransohoff R. Call for papers: Neurology: Neuroimmunology and Neuroinflammation, a new neurology journal. Neurology. 2014;82:648–9.Google Scholar
- 23.Schaefer A, Burmann I, Regenthal R, Arelin K, Barth C, Pampel A, et al. Serotonergic modulation of intrinsic functional connectivity. Cur Biol. 2014. doi: 10.1016/j.cub.2014.08.024.
- 27.Tobinick EL, Gross H. Rapid cognitive improvement in Alzheimer’s disease following perispinal etanercept administration. J Neuroinflamm. 2008;5:2.Google Scholar
- 30.Ignatowski TA, Noble BK, Wright JR, Gorfien JL, Heffner RR, Spengler RN. Neuronal-associated tumor necrosis factor (TNF alpha): its role in noradrenergic functioning and modification of its expression following antidepressant drug administration. J Neuroimmunol. 1997;79(1):84–90.PubMedGoogle Scholar
- 35.Olmos G, Llado J. Tumor necrosis factor alpha: a link between neuroinflammation and excitotoxicity. Mediat inflamm. 2014;2014:861231.Google Scholar
- 38.Whitlock DR. Comment on: “Perispinal etanercept for post-stroke neurological and cognitive dysfunction: scientific rationale and current evidence”. CNS Drugs. 2014. doi: 10.1007/s40263-014-0211-1.
- 44.OCEBM Levels of Evidence Working Group. The Oxford 2011 levels of evidence. Oxford Centre for Evidence-Based Medicine. 2011. http://www.cebm.net/index.aspx?o=5653. Accessed 9 Oct 2014.
- 46.US FDA. Guidance for clinical investigators, spon`sors, and IRBs. Investigational new drug applications (INDs)—determining whether human research studies can be conducted without an IND. 2013. http://www.fda.gov/downloads/Drugs/Guidances/UCM229175.pdf. Accessed 9 Oct 2014.
- 51.Trudeau DL. The value of observational studies in neurotherapy. J Neurother. 2001;4(3):1–4.Google Scholar
- 62.Tobinick E, Rodriguez-Romanacce H, Levine A, Ignatowski TA, Spengler RN. Immediate neurological recovery following perispinal etanercept years after brain injury. Clin Drug Invest 2014; 34(5):361-66.Google Scholar
- 66.Holmes C, Butchart J, Wolfe L, Davies L, Dodge S, Lewsey I, et al. The safety and tolerability of etanercept in Alzheimer’s disease (STEADI-09): a phase II double blind randomised placebo controlled trial 2014. Copenhagen: Alzheimer’s Association International Conference; 2014.Google Scholar
- 69.Ohtori S, Miyagi M, Eguchi Y, Inoue G, Orita S, Ochiai N, et al. Epidural administration of spinal nerves with the tumor necrosis factor-alpha inhibitor, etanercept, compared with dexamethasone for treatment of sciatica in patients with lumbar spinal stenosis: a prospective randomized study. Spine. 2012;37(6):439–44.PubMedGoogle Scholar
- 70.Olmarker K, Rydevik B. Selective inhibition of tumor necrosis factor-alpha prevents nucleus pulposus-induced thrombus formation, intraneural edema, and reduction of nerve conduction velocity: possible implications for future pharmacologic treatment strategies of sciatica. Spine. 2001;26(8):863–9.PubMedGoogle Scholar
- 71.Sainoh T, Orita S, Yamauchi K, Suzuki M, Sakuma Y, Kubota G, et al. Intradiscal administration of tumor necrosis factor-alpha inhibitor, etanercept, clinically improves intractable discogenic low back pain. Glob Spine J. 2014. doi: 10.1055/s-0034-1376544.
- 80.Tobinick E, Vega CP. The cerebrospinal venous system: anatomy, physiology, and clinical implications. Med Gen Med. 2006;8(1):53.Google Scholar
- 82.Ignatowski TA, Spengler RN, Dhandapani KM, Folkersma H, Butterworth RF, Tobinick E. Perispinal etanercept for post-stroke neurological and cognitive dysfunction: scientific rationale and current evidence. CNS Drugs. 2014.Google Scholar
- 83.Ye J, Jiang R, Cui M, Zhu B, Sun L, Wang Y, et al. Etanercept reduces neuroinflammation and lethality in mouse model of Japanese encephalitis. J Infect Dis. 2014;210(6):875-89.Google Scholar
- 84.Winkelstein BA, Allen KD, Setton LA. Chapter 19: intervertebral disc herniation: pathophysiology and emerging therapies. In: Shapiro IM, Risbud MV, editors. The intervertebral disc. Wien: Springer; 2014.Google Scholar
- 85.Wilcox KS, Vezzani A. Does brain inflammation mediate pathological outcomes in epilepsy? Adv Exp Med Biol. 2014;813:169-83.Google Scholar
- 87.Walters ET. Neuroinflammatory contributions to pain after SCI: roles for central glial mechanisms and nociceptor-mediated host defense. Exp Neurol. 2014;258C:48–61.Google Scholar
- 88.Viviani B, Boraso M, Marchetti N, Marinovich M. Perspectives on neuroinflammation and excitotoxicity: a neurotoxic conspiracy? Neurotoxicology. 2014;43:10-20.Google Scholar
- 89.Topdag M, Iseri M, Topdag DO, Kokturk S, Ozturk M, Iseri P. The effect of etanercept and methylprednisolone on functional recovery of the facial nerve after crush injury. Otol Neurotol. 2014;35(7):1277-83.Google Scholar
- 90.Sun Q, Hampel H, Blennow K, Lista S, Levey A, Tang B, et al. Increased plasma TACE activity in subjects with mild cognitive impairment and patients with Alzheimer’s disease. J Alzheimer’s Dis. 2014;41(3):877–86.Google Scholar
- 91.Siniscalchi A, Gallelli L, Malferrari G, Pirritano D, Serra R, Santangelo E, et al. Cerebral stroke injury: the role of cytokines and brain inflammation. J Basic Clin Physiol Pharmacol. 2014;25(2):131-7.Google Scholar
- 93.Najem D, Bamji-Mirza M, Chang N, Liu QY, Zhang W. Insulin resistance, neuroinflammation, and Alzheimer’s disease. Rev Neurosci. 2014;25(4):509-25.Google Scholar
- 97.Ferreira ST, Clarke JR, Bomfim TR, De Felice FG. Inflammation, defective insulin signaling, and neuronal dysfunction in Alzheimer’s disease. Alzheimer’s dement J Alzheimer’s Assoc. 2014;10(1S):S76–83.Google Scholar
- 98.Faingold CL. Network control mechanisms: cellular inputs, neuroactive substances, and synaptic changes. In: Faingold CL, Blumenfeld H, editors. Neuronal networks in brain function. CNS Disorders, and Therapeutics: Elsevier; 2014.Google Scholar
- 99.Ekici MA, Uysal O, Cikriklar HI, Ozbek Z, Turgut Cosan D, Baydemir C, et al. Effect of etanercept and lithium chloride on preventing secondary tissue damage in rats with experimental diffuse severe brain injury. Eur Rev Med Pharmacol Sci. 2014;18(1):10–27.Google Scholar
- 102.Works MG, Koenig JB, Sapolsky RM. Soluble TNF receptor 1-secreting ex vivo-derived dendritic cells reduce injury after stroke. J Cereb Blood Flow Metab. 2013;33(9):1376-85.Google Scholar
- 107.Lei B, Dawson HN, Roulhac-Wilson B, Wang H, Laskowitz DT, James ML. Tumor necrosis factor alpha antagonism improves neurological recovery in murine intracerebral hemorrhage. J Neuroinflamm. 2013;10(1):103.Google Scholar
- 108.Kaufman EL, Carl A. Biochemistry of back pain. Open Spine J. 2013;5:12–8.Google Scholar
- 110.Furst DE, Fleischman R, Kalden J, Kavanaugh A, Sieper J, Mease P, et al. Documentation of off-label use of biologics in rheumatoid arthritis. Ann Rheum Dis. 2013;72(Suppl 2):ii35–51.Google Scholar
- 114.Cheong CU, Chang CP, Chao CM, Cheng BC, Yang CZ, Chio CC. Etanercept attenuates traumatic brain injury in rats by reducing brain TNF-alpha contents and by stimulating newly formed neurogenesis. Mediat Inflamm. 2013;2013:620837.Google Scholar
- 115.Butterworth RF. The liver-brain axis in liver failure: neuroinflammation and encephalopathy. Nature Rev Gastroenterol Hepatol. 2013;10(9):522–8.Google Scholar
- 120.Williams M, Coyle JT. Historical perspectives on the discovery and development of drugs to treat neurological disorders. In: Barrett JE, Coyle JT, Williams M, editors. Translational neuroscience: applications in psychiatry, neurology, and neurodevelopmental disorders. New York: Cambridge University Press; 2012. p. 129–48.Google Scholar
- 124.Hrobjartsson A, Gotzsche PC. Placebo interventions for all clinical conditions. Cochrane Database Syst Rev. 2010;(1):CD003974.Google Scholar
Open AccessThis article is distributed under the terms of the Creative Commons Attribution Noncommercial License which permits any noncommercial use, distribution, and reproduction in any medium, provided the original author(s) and the source are credited.